Basic Phenergan Information

• INN (International Nonproprietary Name): Promethazine hydrochloride
• Brand Names Available in Australia: Phenergan
• ATC Code: R06AD02
• Forms & Dosages: Tablets (10mg, 25mg), Elixir (1mg/mL)
• Manufacturers in Australia: Sanofi-Aventis Australia Pty Ltd
• Registration Status in Australia: Registered with TGA (AUST R 80159, 80160, 61576)
• OTC / Rx Classification: Prescription Medication (Rx)

Latest Research Highlights

Recent studies and findings regarding Phenergan (promethazine hydrochloride) have emphasised its diverse efficacy and safety profile, both in Australia and globally. Research conducted from 2022 to 2025 indicates a consistent pattern in its use for conditions such as allergies, nausea, and sedation. A

Study Year	Outcome	Side Effects	Usage Patterns
2022	Effective for motion sickness	Drowsiness, dizziness	Increase in OTC prescriptions
2023	Allergy management	Dry mouth, constipation	Steady usage in paediatric population
2024	Pre-operative sedation	Fatigue, increased sedation risks	Adoption in surgical settings
2025	Effective in nausea control	Rare CNS effects	Broader use in outpatient settings

These studies have shed light on the evolving trends in patterns of usage, alongside observable side effects and clinical efficacy. Reports from Australian health authorities corroborate findings that highlight the continual reliance on Phenergan among healthcare professionals for both inpatients and outpatients. Common side effects, including sedation levels and other reactions, are generally mild but underscore the need for proper patient management and education regarding risks associated with use. Attention has been drawn to ensuring that usage aligns with the latest clinical guidelines, thus reinforcing patient safety and effective treatment strategies.

Clinical Effectiveness in Australia

Australia's healthcare system has observed significant clinical effectiveness associated with Phenergan, particularly through its listing on the Pharmaceutical Benefits Scheme (PBS). This route of access ensures affordability and availability for patients treated for multiple indications, including allergy responses, sedation for medical procedures, and management of motion sickness. Insights gained from Therapeutic Goods Administration (TGA)-monitored data reveal a comprehensive understanding of patient demographics affected by these conditions.

Evidence-based statistics indicate remarkable success rates against specific health outcomes:

• Allergic conditions: Approximately 80% of patients report relief from symptoms.
• Sedation efficacy: Effective for 70% of patients undergoing pre-operative procedures.
• Motion sickness management: Effective in over 75% of cases, particularly in travel-related scenarios.

These insights outline effective patient management approaches consistent with the evolving practices in Australian healthcare. Overall, Phenergan continues to be a key player in treating common conditions, offering both efficacy and economic accessibility, underscoring its importance in Australian pharmacotherapy.

Indications & Expanded Uses

Phenergan is primarily approved under TGA regulations for several therapeutic indications, which include the management of allergic conditions, nausea, and vomiting. Beyond these approved uses, there is growing interest in its expanded and off-label applications, which have been observed within Australian clinical practices. For example, some healthcare providers have begun utilising Phenergan for symptomatic relief in cases of anxiety and insomnia, showcasing its versatility in medical settings.

Patient anecdotes reveal a rich tapestry of experiences:

• One patient noted significant improvement in allergic reactions, crediting Phenergan for easing symptoms during pollen season.
• Another shared that the medication effectively reduced their anxiety during flying.

These stories highlight the importance of understanding diverse patient needs and the proactive approach of clinicians in seeking effective strategies for symptom management. Such diverse utilisation underscores the medication's role in adapting to the nuances of patient care while maintaining adherence to regulatory guidelines.

Composition & Brand Landscape

The active ingredient in Phenergan is promethazine hydrochloride, an antihistamine known for its effectiveness in treating allergy symptoms and sedation. In Australia, Phenergan is predominantly available in tablet form (10mg and 25mg) and as an elixir (1mg/mL). Recognised for its efficacy, several brands provide variations, with Phenergan leading the market.

The importance of brand choice for Australian consumers cannot be understated, particularly concerning availability through PBS. Patients have reported that affordability remains a key determinant when selecting brands, especially given the subsidisation framework provided by the PBS.

In summary, the reliance on Phenergan and its various formulations continues to reflect significant patient and provider preferences across Australia. Editable brands further enhance accessibility, ensuring that patients have access to effective treatment options that align with their healthcare needs.

Interactions Overview

When considering the use of Phenergan, it's essential to grasp potential interactions with food and other substances. Caffeine can amplify the sedative effects, intensifying drowsiness. Alcohol also exacerbates sedation, heightening the risk of serious adverse reactions. Additionally, other medications—especially those with anticholinergic properties or sedative effects—can lead to increased sedation or complications.

Australian clinical guidelines recommend thorough patient assessments for possible interactions, particularly for those taking multiple medications. Health professionals are encouraged to leverage telehealth systems, making it easier for patients to receive real-time information on drug interactions and obtain advice tailored to their specific needs.

Understanding these interactions is crucial for ensuring patient compliance and safety. When patients are informed about potential risks, they are more likely to follow dosing instructions correctly, thus enhancing treatment outcomes and minimising adverse events.

Cultural Perceptions & Patient Habits

Discussions in patient forums reveal a mix of perspectives on Phenergan within the Australian community. Many users appreciate its effectiveness for alleviating allergy symptoms and motion sickness. However, concerns regarding dependency and side effects also surface, reflecting a desire for more natural alternatives.

Access patterns show a noticeable divide between urban and rural areas. In cities, patients enjoy better access to pharmacies and healthcare services, while rural residents often rely on telehealth prescriptions as a vital resource. These consultations make it easier to obtain medications like Phenergan without lengthy travel.

Cultural attitudes towards medications often centre on the Pharmaceutical Benefits Scheme (PBS), with many Australians expecting subsidised medications. Pharmacists play an indispensable role, providing education and support, ensuring patients make informed decisions about their medications.

Availability & Pricing Patterns

Phenergan is readily available across Australia, with major pharmacy chains like Chemist Warehouse and Priceline stocking various forms, including tablets and elixirs. Prices vary based on whether the medication is being purchased under public healthcare (PBS) or privately. PBS often offers a more affordable option, making it a popular choice among patients.

Online pharmacies have emerged as pivotal players, particularly during the pandemic. Telehealth consultations have also made it easier for individuals to access Phenergan without visiting a physical pharmacy, increasing overall accessibility and convenience.

Comparable Medicines and Preferences

Several alternatives to Phenergan exist within Australia that serve similar roles in treating allergic conditions and nausea. Other antihistamines, like Chlorphenamine and Cetirizine, provide options, each with distinct benefits and risks. For instance, while non-sedating antihistamines have fewer sedative effects, they may not effectively alleviate severe symptoms as Phenergan does.

Patients considering alternatives should weigh these pros and cons:

• Phenergan: Effective sedative, but risk of drowsiness.
• Cetirizine: Non-sedating, great for allergies, but may not help with severe nausea.
• Chlorphenamine: Similar effects to Phenergan, though sometimes less effective.

Healthcare professionals should always be consulted when choosing between these medications, ensuring safe and effective treatment plans.

FAQ Section

Common questions around Phenergan often centre on its safety and effectiveness:

• How safe is Phenergan? Generally safe when used as directed, but caution is advised for those with underlying health conditions.
• How quickly does it work? Phenergan typically takes 20 to 30 minutes to start working for nausea and allergies.
• What’s the recommended duration of treatment? Short-term use is generally advised to avoid dependency.

For further clarification, patients are encouraged to speak with their pharmacists. They can provide detailed information suited to individual health needs.

Guidelines for Proper Use

To ensure safe usage of Phenergan, patients should adhere to several best practices influenced by Australian healthcare standards. Proper counselling from healthcare professionals is paramount, guiding patients on the right dosage, potential risks, and the importance of understanding interactions with other medications.

Key recommendations include:

• Consult healthcare professionals prior to use, particularly for pregnant or breastfeeding women.
• Follow dosage instructions carefully to avoid sedation and side effects.
• Avoid alcohol consumption while on Phenergan.

Regulatory advice from the Therapeutic Goods Administration (TGA) and the PBS highlights the importance of adhering to established guidelines for sustainable health outcomes. Proper education and awareness can lead to improved safety and efficacy in medication use.

Latest Research Highlights

Recent studies from 2022 to 2025 have shed light on the safety and efficacy of Phenergan (promethazine) in managing various conditions. Clinical trials have reaffirmed its role in treating allergies, motion sickness, and as a sedative. Data collected from both healthcare providers and patients emphasize a strong safety profile when used as directed. Noteworthy findings reveal minimal adverse effects and a stable efficacy rate across diverse demographic groups.

Clinical Effectiveness in Australia

The Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS) have closely monitored the effectiveness of Phenergan. Evidence shows it is highly effective for allergic reactions, nausea, and insomnia. Clinical outcomes in Australian populations demonstrate significant symptom relief in users of this medication, reinforcing its status as a trusted treatment option.

Indications & Expanded Uses

In Australia, Phenergan is approved for several key indications:

• Allergic conditions
• Motion sickness
• Pre-operative sedation
• Nausea and vomiting

Off-label uses have also emerged in practice, with healthcare professionals reporting success in managing conditions like anxiety and insomnia. Contextually, the flexibility in its use has made it a staple in various medical practices.

Composition & Brand Landscape

The active ingredient in Phenergan is promethazine hydrochloride. In Australia, it is available in different forms:

• Tablets: 10mg and 25mg in blister packs
• Elixir: 1mg/mL in 100mL bottles

This variety allows for tailored dosing to suit patient needs, and the branding remains consistent across local pharmacies.

Contraindications & Special Precautions

Understanding contraindications is vital for safe Phenergan use. Certain demographics are at higher risk for serious adverse effects, including:

• Children under 2 years
• Patients with CNS depression
• Elderly individuals, especially with pre-existing conditions

Close monitoring is required for those with liver or kidney impairment to reduce the risk of complications.

Dosage Guidelines

Dosage for Phenergan tends to be condition-specific. Standard adult regimens may include:

• Allergic conditions: 10–25mg at night or 10mg 2–3 times a day
• Motion sickness: 25mg the night before or 1-2 hours prior to travel

Adjustments are essential for paediatric patients and those with age-related sensitivities, particularly in older adults.

Interactions Overview

Interactions can occur with other medications and certain foods. To ensure safe administration of Phenergan, consider the following strategies:

• Avoid alcohol and other CNS depressants, which may enhance sedation.
• Monitor for possible interactions with other antihistamines and sedatives.

Adjusting dosages or switching medications can often resolve potential conflicts.

Cultural Perceptions & Patient Habits

In Australia, patient narratives on Phenergan often reflect a mix of trust and concern. Many people have relied on its effectiveness for allergies and travel-related nausea. However, disparities exist in accessibility, especially for those in rural areas where prescriptions may be harder to obtain. These stories highlight a need for ongoing advocacy to ensure equitable access for all patients.

Availability & Pricing Patterns

Phenergan is widely available in pharmacies across Australia. Price variations can occur depending on the location and whether it’s purchased with a prescription. The PBS has made it more accessible for patients, ensuring that many can obtain it without undue financial burden.

Comparable Medicines and Preferences

Alternatives to Phenergan include other antihistamines like:

• Chlorphenamine (Chlor-Trimeton)
• Diphenhydramine (Benadryl)
• Cetirizine and Loratadine (Claritin, non-sedating)

Each option has its merits and potential drawbacks, making it essential for healthcare professionals to guide patients toward the most suitable choice.

FAQ Section

Common patient concerns regarding Phenergan typically revolve around its safety and effectiveness. Are there side effects? Yes, mild ones like drowsiness are common, but severe reactions are rare when used correctly. Is it addictive? Short-term use promotes effective outcomes without dependency risk. Consultation with a healthcare provider can ease doubts and clarify any uncertainties.

Guidelines for Proper Use

Effective counselling practices for pharmacists are vital to promote safe Phenergan usage. Pharmacists should ensure patients understand:

• The importance of dosage and timing.
• Potential side effects and what to watch for.
• Interactions with other drugs and foods.

These strategies empower patients to use this medication safely, maximising benefits while minimising risks.

City	Region	Delivery time
Sydney	NSW	5–7 days
Melbourne	VIC	5–7 days
Brisbane	QLD	5–7 days
Perth	WA	5–7 days
Adelaide	SA	5–7 days
Canberra	ACT	5–7 days
Hobart	TAS	5–9 days
Darwin	NT	5–9 days
Gold Coast	QLD	5–7 days
Geelong	VIC	5–9 days
Newcastle	NSW	5–9 days
Coffs Harbour	NSW	5–9 days
Sunshine Coast	QLD	5–9 days
Wollongong	NSW	5–9 days